STAT17h
Pharmalittle: We’re reading about an FDA hold on an Amgen obesity drug, imported Canadian drugs, and more
The U.S. Food and Drug Administration ordered a hold on a study of an early-stage obesity drug being developed by Amgen, another potential setback in the company’s efforts to join the booming weight ...
KYW Radio Philadelphia on MSN2d
Medical Report: FDA approves weight loss drug to treat sleep apnea
As many as 17% of men and 34% of women in the United States suffer from sleep apnea, and the numbers are increasing. KYW ...
The Straits Times15d
New obesity benchmark adds body fat, organ health to BMI
A new generation of obesity drugs – such as Novo Nordisk A/S’ Wegovy and Eli Lilly and Company’s Zepbound – is changing the perception of obesity as a multifaceted illness that requires ...
The Boston Globe16d
What’s behind the meteoric rise of weight-loss drugs in Massachusetts?
About 140,400 obese patients in Massachusetts were prescribed medications such as Wegovy and Zepbound in 2024, a 255 percent increase from 2023, according to a Globe analysis of insurance claims ...
MarketWatch16d
Medicare can cover Zepbound for sleep apnea, creating a significant opportunity for Eli Lilly
Medicare drug plans can now cover Eli Lilly & Co.’s obesity drug Zepbound as a treatment for obstructive sleep apnea, news that’s expected to prove a big boost for the drug company.
MarketWatch16d
Mounjaro and Zepbound sales disappoint, and Eli Lilly’s stock is dropping
Shares of Eli Lilly & Co. were headed for their worst day in nearly four years on Tuesday after the drugmaker provided a fourth-quarter revenue outlook that was below expectations, citing slower ...
Investopedia17d
Eli Lilly's Zepbound Can Now Be Covered by Medicare to Treat Sleep Apnea
Shelby Knowles / Bloomberg via Getty Images Eli Lilly's Zepbound can be covered by Medicare Part D plans after the FDA approved the drug as a treatment for sleep apnea last month. Weight loss ...
The Motley Fool19d
3 Unstoppable Stocks to Buy in 2025
The pharmaceutical giant has loads of potential just due to its fast-growing GLP-1 drugs, Mounjaro and Zepbound. The former is a treatment for diabetes while the latter is its recently approved ...
The Motley Fool21d
Has Eli Lilly Stock Peaked?
It also had multiple products that generated over $1 billion in revenue, including its top GLP-1 drugs, Mounjaro ($3.1 billion) and Zepbound ($1.3 billion). Late last year, regulators approved ...
STAT22d
Eli Lilly is considering offering more Zepbound doses in vials at lower cost
SAN FRANCISCO — When Eli Lilly last year started offering lower-priced vials of its blockbuster obesity drug Zepbound, which were previously sold in injectable pens, it framed the move as a way ...
MedCity News22d
At JPM, Eli Lilly’s CEO Explains Why Mounjaro, Zepbound Sales Were Lower Than Expected
The company attributed the revision to lower-than-expected sales of tirzepatide, marketed as Mounjaro for type 2 diabetes and Zepbound for obesity. “It’s always disappointing to miss your own ...